Schizophrenia

N Engl J Med. 2019 Oct 31;381(18):1753-1761. doi: 10.1056/NEJMra1808803.

Authors

Stephen R Marder¹, Tyrone D Cannon¹

Affiliation

¹ From the Section on Psychosis, Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles, and the Veterans Affairs Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles (S.R.M.); and the Departments of Psychology and Psychiatry, Yale University, New Haven, CT (T.D.C.).

PMID: 31665579
DOI: 10.1056/NEJMra1808803

No abstract available

Publication types

Review

MeSH terms

Antipsychotic Agents / adverse effects
Antipsychotic Agents / therapeutic use*
Combined Modality Therapy
Diagnostic and Statistical Manual of Mental Disorders
Dopamine / metabolism
Humans
Models, Neurological
Psychotherapy
Schizophrenia* / diagnosis
Schizophrenia* / etiology
Schizophrenia* / metabolism
Schizophrenia* / therapy

Substances

Antipsychotic Agents
Dopamine